551 related articles for article (PubMed ID: 16424063)
61. Is race a positive predictor of cancer on repeat prostate biopsy?
Yanke BV; Salzhauer EW; Colon I
J Urol; 2006 Sep; 176(3):1114-7. PubMed ID: 16890704
[TBL] [Abstract][Full Text] [Related]
62. Chemoprevention of prostate cancer through dietary agents: progress and promise.
Syed DN; Khan N; Afaq F; Mukhtar H
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2193-203. PubMed ID: 18006906
[TBL] [Abstract][Full Text] [Related]
63. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
Thompson IM; Chi C; Ankerst DP; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Natl Cancer Inst; 2006 Aug; 98(16):1128-33. PubMed ID: 16912265
[TBL] [Abstract][Full Text] [Related]
64. Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen.
Svatek RS; Lotan Y
Cancer Prev Res (Phila); 2011 Feb; 4(2):277-83. PubMed ID: 21163937
[TBL] [Abstract][Full Text] [Related]
65. Unsuspected Prostate Carcinoma and Prostatic Intraepithelial Neoplasm in Taiwanese Patients Undergoing Cystoprostatectomy.
Yang CR; Ou YC; Ho HC; Kao YL; Cheng CL; Chen JT; Chen LP; Ho WL
Mol Urol; 1999; 3(1):33-39. PubMed ID: 10851294
[TBL] [Abstract][Full Text] [Related]
66. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting.
Naslund MJ; Gilsenan AW; Midkiff KD; Bown A; Wolford ET; Wang J
Int J Clin Pract; 2007 Sep; 61(9):1437-45. PubMed ID: 17686091
[TBL] [Abstract][Full Text] [Related]
67. [Practical follow-up of a patient treated with finasteride in screening for prostate cancer].
Villers A
Prog Urol; 2008 Apr; 18 Suppl 3():S58-62. PubMed ID: 18455086
[TBL] [Abstract][Full Text] [Related]
68. The cost of prostate cancer chemoprevention: a decision analysis model.
Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1485-9. PubMed ID: 16896037
[TBL] [Abstract][Full Text] [Related]
69. Effects of one-year treatment with isoflavone extract from red clover on prostate, liver function, sexual function, and quality of life in men with elevated PSA levels and negative prostate biopsy findings.
Engelhardt PF; Riedl CR
Urology; 2008 Feb; 71(2):185-90; discussion 190. PubMed ID: 18308079
[TBL] [Abstract][Full Text] [Related]
70. The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups.
van Adelsberg J; Gann P; Ko AT; Damber JE; Logothetis C; Marberger M; Schmitz-Drager BJ; Tubaro A; Harms CJ; Roehrborn C
Curr Med Res Opin; 2007 Sep; 23(9):2063-70. PubMed ID: 17651539
[TBL] [Abstract][Full Text] [Related]
71. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.
Fleshner N; Gomella LG; Cookson MS; Finelli A; Evans A; Taneja SS; Lucia MS; Wolford E; Somerville MC; Rittmaster R;
Contemp Clin Trials; 2007 Nov; 28(6):763-9. PubMed ID: 17573244
[TBL] [Abstract][Full Text] [Related]
72. Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia.
Mohanty NK; Saxena S; Singh UP; Goyal NK; Arora RP
Urol Oncol; 2005; 23(6):383-5. PubMed ID: 16301113
[TBL] [Abstract][Full Text] [Related]
73. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer.
Schoenfield L; Jones JS; Zippe CD; Reuther AM; Klein E; Zhou M; Magi-Galluzzi C
BJU Int; 2007 Apr; 99(4):770-4. PubMed ID: 17233800
[TBL] [Abstract][Full Text] [Related]
74. Chemoprevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia (HGPIN): a systematic review and adjusted indirect treatment comparison.
Cui K; Li X; Du Y; Tang X; Arai S; Geng Y; Xi Y; Xu H; Zhou Y; Ma W; Zhang T
Oncotarget; 2017 May; 8(22):36674-36684. PubMed ID: 28415774
[TBL] [Abstract][Full Text] [Related]
75. Controlled-release doxazosin in the treatment of benign prostatic hyperplasia.
Hernandez C; Duran R; Jara J; Castaño I; Moralejo M
Prostate Cancer Prostatic Dis; 2005; 8(4):375-80. PubMed ID: 16264771
[TBL] [Abstract][Full Text] [Related]
76. Target populations and strategies for chemoprevention trials of prostate cancer.
Bostwick DG
J Cell Biochem Suppl; 1994; 19():191-6. PubMed ID: 7823591
[TBL] [Abstract][Full Text] [Related]
77. New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer.
Connors SK; Chornokur G; Kumar NB
Nutr Cancer; 2012; 64(1):4-22. PubMed ID: 22098273
[TBL] [Abstract][Full Text] [Related]
78. Green tea catechins suppress the DNA synthesis marker MCM7 in the TRAMP model of prostate cancer.
McCarthy S; Caporali A; Enkemann S; Scaltriti M; Eschrich S; Davalli P; Corti A; Lee A; Sung J; Yeatman TJ; Bettuzzi S
Mol Oncol; 2007 Sep; 1(2):196-204. PubMed ID: 18521193
[TBL] [Abstract][Full Text] [Related]
79. Effects of Green Tea Catechins on Prostate Cancer Chemoprevention: The Role of the Gut Microbiome.
Kumar NB; Hogue S; Pow-Sang J; Poch M; Manley BJ; Li R; Dhillon J; Yu A; Byrd DA
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010981
[TBL] [Abstract][Full Text] [Related]
80. [The use of ProstaDoz in patients with benign prostatic hyperplasia and coexistent high-grade prostatic intraepithelial neoplasia].
Antonov AG; Gordeev VV; Fedorchuk SB; Laptev DO
Urologiia; 2017 Oct; (5):58-62. PubMed ID: 29135144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
